All BC subtypes have the ability to develop bone metastasis; however, luminal subtypes A and B exhibit a higher bone metastasis rate (80.5%) as the first metastatic site, when compared with HER-2 positive (55.6%) and basal-like (41.7%) BCs [24]. This evidence concerns the gene ERBB2 and breast cancer.